ATE353920T1 - Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie - Google Patents

Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie

Info

Publication number
ATE353920T1
ATE353920T1 AT04102692T AT04102692T ATE353920T1 AT E353920 T1 ATE353920 T1 AT E353920T1 AT 04102692 T AT04102692 T AT 04102692T AT 04102692 T AT04102692 T AT 04102692T AT E353920 T1 ATE353920 T1 AT E353920T1
Authority
AT
Austria
Prior art keywords
cam
monoclonal antibodies
antibodies against
cancer therapy
human monoclonal
Prior art date
Application number
AT04102692T
Other languages
English (en)
Inventor
Ton Dr Logtenberg
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE353920T1 publication Critical patent/ATE353920T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04102692T 1999-12-27 2000-12-21 Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie ATE353920T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99204561 1999-12-27

Publications (1)

Publication Number Publication Date
ATE353920T1 true ATE353920T1 (de) 2007-03-15

Family

ID=8241110

Family Applications (3)

Application Number Title Priority Date Filing Date
AT04102692T ATE353920T1 (de) 1999-12-27 2000-12-21 Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie
AT00991344T ATE366419T1 (de) 1999-12-27 2000-12-21 Auswahl von epitop-bindungsfähigen verbindungen aus bibliotheken
AT02077516T ATE386747T1 (de) 1999-12-27 2000-12-21 Antikörper gegen ep-cam

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT00991344T ATE366419T1 (de) 1999-12-27 2000-12-21 Auswahl von epitop-bindungsfähigen verbindungen aus bibliotheken
AT02077516T ATE386747T1 (de) 1999-12-27 2000-12-21 Antikörper gegen ep-cam

Country Status (11)

Country Link
US (2) US20030096225A1 (de)
EP (3) EP1273918B1 (de)
JP (1) JP2003518391A (de)
AT (3) ATE353920T1 (de)
AU (1) AU783148B2 (de)
CA (1) CA2396029A1 (de)
DE (3) DE60035434T2 (de)
DK (1) DK1479696T3 (de)
ES (1) ES2282797T3 (de)
NZ (2) NZ531590A (de)
WO (1) WO2001048485A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
ATE374255T1 (de) * 2002-04-17 2007-10-15 Bioren Inc Doping bei der walk-through-mutagenese
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
CA2503838C (en) * 2003-09-08 2014-08-19 E. I. Du Pont De Nemours And Company Peptide-based conditioners and colorants for hair
EP1737971B1 (de) 2004-01-20 2017-08-16 Merus N.V. Gemische bindender proteine
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US9079942B2 (en) 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
EP2726870B1 (de) 2011-06-29 2018-10-03 Academia Sinica Erfassung, reinigung und freisetzung eines biologischen stoffes anahnd einer oberflächenbeschichtung
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
EP2819695B1 (de) * 2012-03-02 2018-06-27 Academia Sinica Antikörper gegen epithelzelladhäsionsmoleküle (epcam) und anwendungsverfahren dafür
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
TW201623605A (zh) 2014-04-01 2016-07-01 中央研究院 用於癌症診斷及預後之方法及系統
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
WO2019213624A1 (en) * 2018-05-04 2019-11-07 The Regents Of The University Of California Spiked primers for enrichment of pathogen nucleic acids among background of nucleic acids
US11707487B2 (en) 2020-04-13 2023-07-25 Affyimmune Therapeutics, Inc. EpCAM antibody and CAR-T cells
WO2022126084A1 (en) * 2020-12-09 2022-06-16 Affyimmune Therapeutics, Inc. Dual chimeric antigen receptor targeting epcam and icam-1
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DK0934526T3 (da) * 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
US6787638B1 (en) * 1998-12-02 2004-09-07 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use

Also Published As

Publication number Publication date
EP1479696A1 (de) 2004-11-24
DE60038132D1 (de) 2008-04-03
DE60038132T2 (de) 2009-04-02
JP2003518391A (ja) 2003-06-10
AU3244701A (en) 2001-07-09
EP1273918A2 (de) 2003-01-08
DE60033455D1 (de) 2007-03-29
EP1479696B1 (de) 2007-02-14
NZ520074A (en) 2004-04-30
US7777010B2 (en) 2010-08-17
DE60035434T2 (de) 2008-05-15
DK1479696T3 (da) 2007-05-07
US20030096225A1 (en) 2003-05-22
EP1242823B1 (de) 2007-07-04
NZ531590A (en) 2006-01-27
WO2001048485A9 (en) 2002-09-06
ATE386747T1 (de) 2008-03-15
EP1273918B1 (de) 2008-02-20
AU783148B2 (en) 2005-09-29
WO2001048485A3 (en) 2002-01-31
WO2001048485A2 (en) 2001-07-05
EP1242823A2 (de) 2002-09-25
US20030096226A1 (en) 2003-05-22
CA2396029A1 (en) 2001-07-05
ES2282797T3 (es) 2007-10-16
EP1273918A3 (de) 2003-05-02
ATE366419T1 (de) 2007-07-15
DE60033455T2 (de) 2007-11-29
DE60035434D1 (de) 2007-08-16

Similar Documents

Publication Publication Date Title
ATE353920T1 (de) Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
DE69724428D1 (de) Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
DE69433406T2 (de) Antikörper gegen cd40
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
DE69941598D1 (de) Anti-ccr2 antikörper sowie deren verwendung
EP1071458A4 (de) Humanisierter antikörper und dessen verwendungen
ATE483733T1 (de) Hochaffine humane antikörper gegen tumorantigene
DE60018761D1 (de) Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
ID28088A (id) Antibodi untuk cd23, turunan-turunannya dan penggunannya untuk terapi
IN2014DN05011A (de)
EP1572087A4 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
AR026946A1 (es) Osteoprotegerina/receptores de factores de necrosis de tumores
ATE366746T1 (de) Gegen das semp1-protein gerichtete antikörper, verfahren zu deren herstellung, und deren anwendungen
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE221663T1 (de) Prionbindende proteine und deren verwendungen
DE60333585D1 (de) Antikörper gegen menschlichen nogo a und seine pharmazeutische verwendung
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
ATE362490T1 (de) Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
DE69627279T2 (de) Gelierungsbeschleuniger, einen diesen beinhaltenden Injektionsschlamm und dessen Verwendung
DE60014616D1 (de) Antikörper gegen plazentaprotein 13

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1479696

Country of ref document: EP